Open AccessMEG3 LncRNA from Exosomes Released from Cancer-Associated Fibroblasts Enhances Cisplatin Chemoresistance in SCLC via a MiR-15a-5p/CCNE1 Axis
Author(s) -
Yulu Sun,
Guijun Hao,
Mengqi Zhuang,
Huijuan Lv,
Chunhong Liu,
Keli Su
Publication year - 2022
Publication title -
yonsei medical journal/yonsei medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.702
H-Index - 63
eISSN - 1976-2437
pISSN - 0513-5796
DOI - 10.3349/ymj.2022.63.3.229
Subject(s) - meg3 , viability assay , cancer research , cisplatin , microvesicles , microrna , gene silencing , long non coding rna , metastasis , chemistry , cell , biology , cancer , downregulation and upregulation , chemotherapy , biochemistry , gene , genetics
Long non-coding RNAs (lncRNAs) may act as oncogenes in small-cell lung cancer (SCLC). Exosomes containing lncRNAs released from cancer-associated fibroblasts (CAF) accelerate tumorigenesis and confer chemoresistance. This study aimed to explore the action mechanism of the CAF-derived lncRNA maternally expressed gene 3 (MEG3) on cisplatin (DDP) chemoresistance and cell processes in SCLC.